{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T03:29:01Z","timestamp":1767151741276,"version":"build-2238731810"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2010,4,9]],"date-time":"2010-04-09T00:00:00Z","timestamp":1270771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2010,4,9]],"date-time":"2010-04-09T00:00:00Z","timestamp":1270771200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2010,8]]},"DOI":"10.1038\/eye.2010.22","type":"journal-article","created":{"date-parts":[[2010,4,9]],"date-time":"2010-04-09T05:48:19Z","timestamp":1270792099000},"page":"1320-1324","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Blood pressure changes after intravitreal bevacizumab in patients grouped by ocular pathology"],"prefix":"10.1038","volume":"24","author":[{"given":"Y-R","family":"Chung","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E-H","family":"Cho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H M","family":"Lew","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,4,9]]},"reference":[{"key":"BFeye201022_CR1","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/j.ophtha.2006.12.028","volume":"114","author":"JF Arevalo","year":"2007","unstructured":"Arevalo JF, Fromow-Guerra J, Quiroz-Mercado H, Sanchez JG, Wu L, Maia M et al. Primary intravitreal bevacizumab (Avastin) for diabetic macular edema. Ophthalmology 2007; 114: 743\u2013750.","journal-title":"Ophthalmology"},{"key":"BFeye201022_CR2","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1016\/j.ophtha.2005.02.007","volume":"112","author":"S Michels","year":"2005","unstructured":"Michels S, Rosenfeld PJ, Puliafito CA, Marcus EN, Venkatraman AS . Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration. Ophthalmology 2005; 112: 1035\u20131047.","journal-title":"Ophthalmology"},{"key":"BFeye201022_CR3","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1097\/01.iae.0000225766.75009.3a","volume":"26","author":"RM Rich","year":"2006","unstructured":"Rich RM, Resenfeld PJ, Puliafito CA, Dubovy SR, Davis JL, Flynn Jr HW et al. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Retina 2006; 26: 495\u2013511.","journal-title":"Retina"},{"key":"BFeye201022_CR4","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1038\/sj.eye.6703040","volume":"22","author":"K G\u00fcnd\u00fcz","year":"2008","unstructured":"G\u00fcnd\u00fcz K, Bakri SJ . Intravitreal bevacizumab for macular edema secondary to branch retinal vein occlusion. Eye 2008; 22: 1168\u20131171.","journal-title":"Eye"},{"key":"BFeye201022_CR5","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1016\/S0161-6420(96)30420-X","volume":"103","author":"MJ Tolentino","year":"2006","unstructured":"Tolentino MJ, Miller LW, Gragoudas ES, Jakobiec FA, Flynn E, Chatzistefanou K et al. Intravitreal injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate. Ophthalmology 2006; 103: 1820\u20131828.","journal-title":"Ophthalmology"},{"key":"BFeye201022_CR6","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1001\/archopht.1996.01100140172010","volume":"114","author":"MJ Tolentino","year":"1996","unstructured":"Tolentino MJ, Miller JW, Gragoudas ES, Chatzistefanou K, Ferrara N, Adamis AP . Vascular endothelial growth factor is sufficient to produce iris neovascularization and neovascular glaucoma in a nonhuman primate. Arch Ophthalmol 1996; 114: 964\u2013970.","journal-title":"Arch Ophthalmol"},{"key":"BFeye201022_CR7","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/S0002-9394(14)75794-0","volume":"118","author":"AP Adamis","year":"1994","unstructured":"Adamis AP, Miller JW, Bernal MT, D\u2019Amico DJ, Folkman J, Yeo TK et al. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol 1994; 118: 445\u2013450.","journal-title":"Am J Ophthalmol"},{"key":"BFeye201022_CR8","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1056\/NEJM199412013312203","volume":"331","author":"LP Aiello","year":"1994","unstructured":"Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994; 331: 1480\u20131487.","journal-title":"N Engl J Med"},{"key":"BFeye201022_CR9","first-page":"638","volume":"72","author":"J Pe\u2019er","year":"1995","unstructured":"Pe\u2019er J, Shweiki D, Itin A, Hemo I, Gnessin H, Keshet E . Hypoxia-induced expression of vascular endothelial growth factor by retinal cells is a common factor in neovascularizing ocular diseases. Lab Invest 1995; 72: 638\u2013645.","journal-title":"Lab Invest"},{"key":"BFeye201022_CR10","first-page":"855","volume":"37","author":"PF Lopez","year":"1996","unstructured":"Lopez PF, Sippy BD, Lambert M, Thach AB, Hinton DR . Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related membranes. Invest Ophthalmol Vis Sci 1996; 37: 855\u2013868.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"BFeye201022_CR11","first-page":"1929","volume":"37","author":"A Kvanta","year":"1996","unstructured":"Kvanta A, Algvere PV, Berglin L, Seregard S . Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. Invest Ophthalmol Vis Sci 1996; 37: 1929\u20131934.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"BFeye201022_CR12","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s00417-007-0660-z","volume":"246","author":"L Wu","year":"2008","unstructured":"Wu L, Mart\u00ednez-Castellanos MA, Quiroz-Mercado H, Arevalo JF, Berrocal MH, Farah ME et al. Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES). Graefes Arch Clin Exp Ophthalmol 2008; 246: 81\u201387.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"BFeye201022_CR13","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1136\/bjo.2006.099598","volume":"90","author":"AE Fung","year":"2006","unstructured":"Fung AE, Rosenfeld PJ, Reichel E . The international intravitreal bevacizumab safety survey: using the internet to assess drug safety worldwide. Br J Ophthalmol 2006; 90: 1344\u20131349.","journal-title":"Br J Ophthalmol"},{"key":"BFeye201022_CR14","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1093\/annonc\/mdm550","volume":"19","author":"JJ Mourad","year":"2008","unstructured":"Mourad JJ, des Guetz G, Dabbabi H, Levy BI . Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation. Ann Oncol 2008; 19: 927\u2013934.","journal-title":"Ann Oncol"},{"key":"BFeye201022_CR15","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1111\/j.1600-0420.2006.00819.x","volume":"85","author":"M Kernt","year":"2007","unstructured":"Kernt M, Neubauer AS, Kampik A . Intravitreal bevacizumab (Avastin) treatment is safe in terms of intraocular and blood pressure. Acta Ophthalmol Scand 2007; 85: 119\u2013120.","journal-title":"Acta Ophthalmol Scand"},{"key":"BFeye201022_CR16","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1097\/IAE.0b013e3181b21056","volume":"29","author":"K Lee","year":"2009","unstructured":"Lee K, Yang H, Lim H, Lew HM . A prospective study of blood pressure and intraocular pressure changes in hypertensive and nonhypertensive patients after intravitreal bevacizumab injection. Retina 2009; 29: 1409\u20131417.","journal-title":"Retina"},{"key":"BFeye201022_CR17","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/j.ophtha.2007.01.017","volume":"114","author":"SJ Bakri","year":"2007","unstructured":"Bakri SJ, Snyder MR, Reid JM, Pulido JS, Singh RJ . Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology 2007; 114: 855\u2013859.","journal-title":"Ophthalmology"},{"key":"BFeye201022_CR18","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s10792-008-9221-7","volume":"29","author":"F Ziemssen","year":"2009","unstructured":"Ziemssen F, Zhu Q, Peters S, Grisanti S, El Wardani M, Szurman P et al. Intensified monitoring of circadian blood pressure and heart rate before and after intravitreous injection of bevacizumab: preliminary findings of a pilot study. Int Ophthalmol 2009; 29: 213\u2013224.","journal-title":"Int Ophthalmol"},{"key":"BFeye201022_CR19","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1081\/CBI-120019342","volume":"20","author":"M Ceyhan","year":"2003","unstructured":"Ceyhan M, Gunaydin S, Yorgancioglu C, Zorlutuna Y, Uluoglu C, Zengil H . Comparison of circadian rhythm characteristics of blood pressure and heart rate in patients before and after elective coronary artery bypass surgery. Chronobiol Int 2003; 20: 337\u2013349.","journal-title":"Chronobiol Int"}],"updated-by":[{"DOI":"10.1038\/eye.2011.266","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2011,12,8]],"date-time":"2011-12-08T00:00:00Z","timestamp":1323302400000}},{"DOI":"10.1038\/eye.2010.143","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2010,11,11]],"date-time":"2010-11-11T00:00:00Z","timestamp":1289433600000}}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/eye201022.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/eye201022","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/eye201022.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,9]],"date-time":"2025-08-09T03:43:36Z","timestamp":1754711016000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/eye201022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4,9]]},"references-count":19,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2010,8]]}},"alternative-id":["BFeye201022"],"URL":"https:\/\/doi.org\/10.1038\/eye.2010.22","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,4,9]]},"assertion":[{"value":"26 October 2009","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2010","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2010","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2010","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2011","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Erratum","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"An Erratum to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/eye.2011.266","URL":"https:\/\/doi.org\/10.1038\/eye.2011.266","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}